Later, with prostate cancer progression, PAcP expression by the cancer is typically lost, limiting its value as a clinical epidemiological biomarker, a use that has been supplanted by prostate-specific antigen (PSA) [12]. This evidence concerns the gene KLK3 and Familial prostate cancer.